NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Analysts
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the […]
More Stories
What Makes Live Dealer Casino Games Feel Like the Real Table?
There is a noticeable difference between watching an animated roulette wheel and seeing a real ball circle a physical wheel....
How to Match Native Display Ads to Your Content and Campaign Goals
A native campaign can struggle when the ad attracts one kind of interest but the destination asks for something different....
491 Fugitives Hiding in Public Housing Arrested in Nationwide Sweep
By Naveen Athrappully A multi-month law enforcement operation has led to the arrests of 491 criminal fugitives living in government-assisted...
Trump Doubles Down on $5,000 Payments Tied to Midterm Results
By Jack Phillips President Donald Trump on Monday released a new advertisement that doubled down on his promise to send...
Zelenskyy Says Strikes on Russian Refineries Will Continue If Putin Rejects Energy Ceasefire
By Owen Evans Ukraine will continue its long-range strikes against Russia if Moscow doesn’t accept an energy truce, President Volodymyr...
Federal Agents Search Rep. Ilhan Omar’s Home: What We Know
By Jack Phillips The Washington home of Rep. Ilhan Omar (D-Minn.) was searched on Monday by federal agents as part...